Contrasting IceCure Medical (NASDAQ:ICCM) & Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Insider & Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Nyxoah and IceCure Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33 million	5.47	-$101.92 million	($2.52)	-0.63
IceCure Medical	$3.38 million	2.33	-$15.06 million	($8.52)	-0.27

IceCure Medical has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nyxoah has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Nyxoah and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
IceCure Medical	2	0	3	0	2.20

Nyxoah presently has a consensus price target of $4.26, indicating a potential upside of 166.38%. IceCure Medical has a consensus price target of $52.50, indicating a potential upside of 2,182.61%. Given IceCure Medical’s higher probable upside, analysts clearly believe IceCure Medical is more favorable than Nyxoah.

Profitability

This table compares Nyxoah and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
IceCure Medical	-427.67%	-174.26%	-112.58%

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.